BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15749638)

  • 1. Targeted cancer therapies.
    Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
    Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted therapies of cancer: not lost in translation].
    Blay JY
    Bull Cancer; 2006 Aug; 93(8):799-804. PubMed ID: 16935785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
    Karakosta A; Golias Ch; Charalabopoulos A; Peschos D; Batistatou A; Charalabopoulos K
    J Exp Clin Cancer Res; 2005 Dec; 24(4):505-14. PubMed ID: 16471312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for breast cancer.
    Tookman L; Roylance R
    Br Med Bull; 2010; 96():111-29. PubMed ID: 20870669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapies in breast cancer.
    Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.